ASX:KZA

Kazia Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume47,736 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive KZA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and the University of Newcastle. Kazia Therapeutics Limited also has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug paxalisib in primary central nervous system lymphoma; Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083; and Joan & Sanford I Weill Medical College of Cornell University for Phase II clinical study using Paxalisib in combination with ketogenic diet for glioblastoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Kazia Therapeutics (ASX:KZA) Frequently Asked Questions

What stocks does MarketBeat like better than Kazia Therapeutics?

Wall Street analysts have given Kazia Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kazia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 48, Pay $738.46k)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons), Company Sec. (Age 61, Pay $142.88k)
  • Kym Robins, Director of Marketing & Communications

Who are some of Kazia Therapeutics' key competitors?

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the ASX under the ticker symbol "KZA."

How much money does Kazia Therapeutics make?

Kazia Therapeutics has a market capitalization of $0.00 and generates $363,489.00 in revenue each year.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

The company can be reached via phone at 61 2 9472 4101.


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.